Author

Henningfield JE

Jack Henningfield, Ph.D. Vice President, Research, Health Policy, and Abuse Liability; Professor, Adjunct, Behavioral Biology, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine - Cited by 25,002 - Pharmaceutical abuse potential assessment - harm reduction - Nicotine - Opioids - Kratom

Biography

Henningfield JE works at PinneyAssociates, Montgomery Lane, Bethesda, USA. Author research interest is in Psychiatry and Behavioral Sciences and his research interests reflect in his wide range of publications in various national and international journals. 
Title
Cited by
Year
Kratom as a substitute for opioids: results from an online survey
MA Coe, JL Pillitteri, MA Sembower, KK Gerlach, JE HenningfieldDrug and alcohol dependence 202, 24-32, 2019201
113
2019
Kratom policy: the challenge of balancing therapeutic potential with public safety
WC Prozialeck, BA Avery, EW Boyer, O Grundmann, JE Henningfield, ...International Journal of Drug Policy 70, 70-77, 2019201
84
2019
Understanding kratom use: a guide for healthcare providers
MT Swogger, KE Smith, A Garcia-Romeu, O Grundmann, CA Veltri, ...Frontiers in pharmacology 13, 801855, 2022202
39
2022
Risk of death associated with kratom use compared to opioids
JE Henningfield, O Grundmann, JK Babin, RV Fant, DW Wang, EJ ConePreventive medicine 128, 105851, 2019201
36
2019
Abuse liability assessment of the JUUL system in four flavors relative to combustible cigarette, nicotine gum and a comparator electronic nicotine delivery system among adult …
NI Goldenson, AR Buchhalter, EM Augustson, ML Rubinstein, ...Drug and Alcohol Dependence 217, 108395, 2020202
34
2020
An open-label, randomized, controlled, crossover study to assess nicotine pharmacokinetics and subjective effects of the JUUL system with three nicotine concentrations relative …
NI Goldenson, IM Fearon, AR Buchhalter, JE HenningfieldNicotine and Tobacco Research 23 (6), 947-955, 2021202
25
2021
Is caffeine a drug of dependence? Criteria and comparisons
SJ Heishman, JE HenningfieldCaffeine and Behavior: Current Views & Research Trends, 137-150, 2020202
22
2020
Behavioral economic demand metrics for abuse deterrent and abuse potential quantification
LP Schwartz, PG Roma, JE Henningfield, SR Hursh, EJ Cone, ...Drug and Alcohol Dependence 198, 13-20, 2019201
21
2019
Is kratom (Mitragyna speciosa Korth.) use associated with ECG abnormalities? Electrocardiogram comparisons between regular kratom users and controls
MFI Leong Abdullah, KL Tan, S Narayanan, N Yuvashnee, NJY Chear, ...Clinical Toxicology 59 (5), 400-408, 202119202
19
2021
Abuse liability assessment of the JUUL system in two nicotine concentrations compared to combustible cigarette, nicotine gum and comparator electronic nicotine delivery system
NI Goldenson, AR Buchhalter, EM Augustson, ML Rubinstein, D Van Hoof, ...Drug and Alcohol Dependence 217, 108441, 2020202
16
2020
Kratom use in the United States: a diverse and complex profile
O Grundmann, JK Babin, JE Henningfield, A Garcia-Romeu, AC Kruegel, ...Addiction (Abingdon, England) 1 (1), 202, 2021202
16
2021
The use of kratom (Mitragyna speciosa Korth.) among people who co-use heroin and methamphetamine in Malaysia
D Singh, S Narayanan, B Vicknasingam, WC Prozialeck, KE Smith, ...Journal of addiction medicine 16 (2), 223-228, 2022202
14
2022
Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care
S Ross, M Agrawal, RR Griffiths, C Grob, A Berger, JE HenningfieldNeuropharmacology 216, 109174, 2022202
13
2022
Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users
MJ Shram, RH Spencer, J Qian, CL Munera, ME Lewis, JE Henningfield, ...Clinical and Translational Science 15 (2), 535-547, 2022202
13
2022
Kratom abuse potential 2021: an updated eight factor analysis
JE Henningfield, DW Wang, MA HuestisFrontiers in Pharmacology, 3579, 2022202
11
2022
Abuse potential of lemborexant, a dual orexin receptor antagonist, compared with zolpidem and suvorexant in recreational sedative users
I Landry, N Hall, J Aluri, G Filippov, L Reyderman, B Setnik, ...Journal of Clinical Psychopharmacology 42 (4), 365, 2022202
10
2022
Why we work with the tobacco industry
JR Hughes, KO Fagerstrom, JE Henningfield, B Rodu, JE Rose, ...Addiction 114 (2), 374-375, 2019201
10
2019
The nexus of opioids, pain, and addiction: Challenges and solutions
JE Henningfield, JB Ashworth, KK Gerlach, B Simone, SH SchnollPreventive medicine 128, 105852, 20120
9
2019
Human abuse potential of oral NKTR-181 in recreational opioid users: a randomized, double-blind, crossover study
X Ge, JE Henningfield, S Siddhanti, J Jobes, L Lu, S Xie, M Ziola, D Kelsh, ...Pain Medicine 21 (2), e114-e126, 2020202
9
2020
We need better estimates of kratom use prevalence
JE Henningfield, O Grundmann, A Garcia-Romeu, MT SwoggerAmerican journal of preventive medicine 62 (1), 132-133, 2022202
9
2022

Referred From: https://scholar.google.com/citations?user=ROSREckAAAAJ&hl=en&oi=sra

Cited by
Citations 25002
h-index 88
i10-index 303
Open Access Journals